ID   AAPK1_HUMAN             Reviewed;         559 AA.
AC   Q13131; A8MTQ6; B2R7E1; O00286; Q5D0E1; Q86VS1; Q9UNQ4;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   28-JUL-2009, sequence version 4.
DT   12-OCT-2022, entry version 230.
DE   RecName: Full=5'-AMP-activated protein kinase catalytic subunit alpha-1;
DE            Short=AMPK subunit alpha-1;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:32029622};
DE   AltName: Full=Acetyl-CoA carboxylase kinase;
DE            Short=ACACA kinase;
DE            EC=2.7.11.27 {ECO:0000250|UniProtKB:P54645};
DE   AltName: Full=Hydroxymethylglutaryl-CoA reductase kinase;
DE            Short=HMGCR kinase;
DE            EC=2.7.11.31 {ECO:0000250|UniProtKB:P54645};
DE   AltName: Full=Tau-protein kinase PRKAA1;
DE            EC=2.7.11.26 {ECO:0000250|UniProtKB:P54645};
GN   Name=PRKAA1; Synonyms=AMPK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   LEU-10.
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3-559 (ISOFORM 1).
RC   TISSUE=Mammary gland;
RA   Yano K.;
RT   "Nucleotide sequence of cDNA for human AMP-activated protein kinase alpha-
RT   1.";
RL   Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 5-559 (ISOFORM 1).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 9-559 (ISOFORM 1).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for 300
RT   previously undefined genes expressed in CD34+ hematopoietic stem/progenitor
RT   cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 36-209 (ISOFORM 1).
RC   TISSUE=Intestine;
RA   Taboada E.N., Hickey D.A.;
RL   Submitted (APR-1995) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 303-559 (ISOFORMS 1/2).
RC   TISSUE=Liver;
RX   PubMed=8557660; DOI=10.1074/jbc.271.2.611;
RA   Stapleton D., Mitchelhill K.I., Gao G., Widmer J., Michell B.J., Teh T.,
RA   House C.M., Fernandez C.S., Cox T., Witters L.A., Kemp B.E.;
RT   "Mammalian AMP-activated protein kinase subfamily.";
RL   J. Biol. Chem. 271:611-614(1996).
RN   [8]
RP   DOMAIN AIS.
RX   PubMed=9857077; DOI=10.1074/jbc.273.52.35347;
RA   Crute B.E., Seefeld K., Gamble J., Kemp B.E., Witters L.A.;
RT   "Functional domains of the alpha1 catalytic subunit of the AMP-activated
RT   protein kinase.";
RL   J. Biol. Chem. 273:35347-35354(1998).
RN   [9]
RP   FUNCTION.
RX   PubMed=11554766; DOI=10.1006/bbrc.2001.5627;
RA   Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.;
RT   "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated
RT   protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-
RT   ribofuranoside, in a human hepatocellular carcinoma cell line.";
RL   Biochem. Biophys. Res. Commun. 287:562-567(2001).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF EP300.
RX   PubMed=11518699; DOI=10.1074/jbc.c100316200;
RA   Yang W., Hong Y.H., Shen X.Q., Frankowski C., Camp H.S., Leff T.;
RT   "Regulation of transcription by AMP-activated protein kinase:
RT   phosphorylation of p300 blocks its interaction with nuclear receptors.";
RL   J. Biol. Chem. 276:38341-38344(2001).
RN   [11]
RP   ACTIVITY REGULATION.
RX   PubMed=11602624; DOI=10.1172/jci13505;
RA   Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M.,
RA   Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J.,
RA   Moller D.E.;
RT   "Role of AMP-activated protein kinase in mechanism of metformin action.";
RL   J. Clin. Invest. 108:1167-1174(2001).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF CFTR.
RX   PubMed=12519745; DOI=10.1152/ajpcell.00227.2002;
RA   Hallows K.R., Kobinger G.P., Wilson J.M., Witters L.A., Foskett J.K.;
RT   "Physiological modulation of CFTR activity by AMP-activated protein kinase
RT   in polarized T84 cells.";
RL   Am. J. Physiol. 284:C1297-C1308(2003).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF TSC2.
RX   PubMed=14651849; DOI=10.1016/s0092-8674(03)00929-2;
RA   Inoki K., Zhu T., Guan K.L.;
RT   "TSC2 mediates cellular energy response to control cell growth and
RT   survival.";
RL   Cell 115:577-590(2003).
RN   [14]
RP   PHOSPHORYLATION AT THR-183, AND ACTIVITY REGULATION.
RX   PubMed=14976552; DOI=10.1038/sj.emboj.7600110;
RA   Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A., Boudeau J.,
RA   Hawley S.A., Udd L., Maekelae T.P., Hardie D.G., Alessi D.R.;
RT   "LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily,
RT   including MARK/PAR-1.";
RL   EMBO J. 23:833-843(2004).
RN   [15]
RP   PHOSPHORYLATION AT THR-183, AND ACTIVITY REGULATION.
RX   PubMed=16054095; DOI=10.1016/j.cmet.2005.05.009;
RA   Hawley S.A., Pan D.A., Mustard K.J., Ross L., Bain J., Edelman A.M.,
RA   Frenguelli B.G., Hardie D.G.;
RT   "Calmodulin-dependent protein kinase kinase-beta is an alternative upstream
RT   kinase for AMP-activated protein kinase.";
RL   Cell Metab. 2:9-19(2005).
RN   [16]
RP   PHOSPHORYLATION AT THR-183, AND ACTIVITY REGULATION.
RX   PubMed=15980064; DOI=10.1074/jbc.m503824200;
RA   Hurley R.L., Anderson K.A., Franzone J.M., Kemp B.E., Means A.R.,
RA   Witters L.A.;
RT   "The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated
RT   protein kinase kinases.";
RL   J. Biol. Chem. 280:29060-29066(2005).
RN   [17]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027;
RA   Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J.,
RA   Thompson C.B.;
RT   "AMP-activated protein kinase induces a p53-dependent metabolic
RT   checkpoint.";
RL   Mol. Cell 18:283-293(2005).
RN   [18]
RP   INTERACTION WITH FNIP1.
RX   PubMed=17028174; DOI=10.1073/pnas.0603781103;
RA   Baba M., Hong S.-B., Sharma N., Warren M.B., Nickerson M.L., Iwamatsu A.,
RA   Esposito D., Gillette W.K., Hopkins R.F. III, Hartley J.L., Furihata M.,
RA   Oishi S., Zhen W., Burke T.R. Jr., Linehan W.M., Schmidt L.S., Zbar B.;
RT   "Folliculin encoded by the BHD gene interacts with a binding protein,
RT   FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15552-15557(2006).
RN   [19]
RP   DOMAIN AIS, AND MUTAGENESIS OF VAL-307.
RX   PubMed=17088252; DOI=10.1074/jbc.m605790200;
RA   Pang T., Xiong B., Li J.Y., Qiu B.Y., Jin G.Z., Shen J.K., Li J.;
RT   "Conserved alpha-helix acts as autoinhibitory sequence in AMP-activated
RT   protein kinase alpha subunits.";
RL   J. Biol. Chem. 282:495-506(2007).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF FOXO3.
RX   PubMed=17711846; DOI=10.1074/jbc.m705325200;
RA   Greer E.L., Oskoui P.R., Banko M.R., Maniar J.M., Gygi M.P., Gygi S.P.,
RA   Brunet A.;
RT   "The energy sensor AMP-activated protein kinase directly regulates the
RT   mammalian FOXO3 transcription factor.";
RL   J. Biol. Chem. 282:30107-30119(2007).
RN   [21]
RP   FUNCTION IN CELL POLARITY.
RX   PubMed=17486097; DOI=10.1038/nature05828;
RA   Lee J.H., Koh H., Kim M., Kim Y., Lee S.Y., Karess R.E., Lee S.H.,
RA   Shong M., Kim J.M., Kim J., Chung J.;
RT   "Energy-dependent regulation of cell structure by AMP-activated protein
RT   kinase.";
RL   Nature 447:1017-1020(2007).
RN   [22]
RP   FUNCTION IN PHOSPHORYLATION OF HDAC5.
RX   PubMed=18184930; DOI=10.2337/db07-0843;
RA   McGee S.L., van Denderen B.J., Howlett K.F., Mollica J., Schertzer J.D.,
RA   Kemp B.E., Hargreaves M.;
RT   "AMP-activated protein kinase regulates GLUT4 transcription by
RT   phosphorylating histone deacetylase 5.";
RL   Diabetes 57:860-867(2008).
RN   [23]
RP   INTERACTION WITH FNIP2.
RX   PubMed=18403135; DOI=10.1016/j.gene.2008.02.022;
RA   Hasumi H., Baba M., Hong S.-B., Hasumi Y., Huang Y., Yao M., Valera V.A.,
RA   Linehan W.M., Schmidt L.S.;
RT   "Identification and characterization of a novel folliculin-interacting
RT   protein FNIP2.";
RL   Gene 415:60-67(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-382, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [26]
RP   FUNCTION IN PHOSPHORYLATION OF RPTOR.
RX   PubMed=18439900; DOI=10.1016/j.molcel.2008.03.003;
RA   Gwinn D.M., Shackelford D.B., Egan D.F., Mihaylova M.M., Mery A.,
RA   Vasquez D.S., Turk B.E., Shaw R.J.;
RT   "AMPK phosphorylation of raptor mediates a metabolic checkpoint.";
RL   Mol. Cell 30:214-226(2008).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [28]
RP   INTERACTION WITH FNIP2.
RX   PubMed=18663353; DOI=10.1038/onc.2008.261;
RA   Takagi Y., Kobayashi T., Shiono M., Wang L., Piao X., Sun G., Zhang D.,
RA   Abe M., Hagiwara Y., Takahashi K., Hino O.;
RT   "Interaction of folliculin (Birt-Hogg-Dube gene product) with a novel
RT   Fnip1-like (FnipL/Fnip2) protein.";
RL   Oncogene 27:5339-5347(2008).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-356; SER-486; THR-490 AND
RP   SER-496, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-32 AND SER-467, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-382, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [32]
RP   FUNCTION IN PHOSPHORYLATION OF KLC1.
RX   PubMed=20074060; DOI=10.1042/bst0380205;
RA   McDonald A., Fogarty S., Leclerc I., Hill E.V., Hardie D.G., Rutter G.A.;
RT   "Cell-wide analysis of secretory granule dynamics in three dimensions in
RT   living pancreatic beta-cells: evidence against a role for AMPK-dependent
RT   phosphorylation of KLC1 at Ser517/Ser520 in glucose-stimulated insulin
RT   granule movement.";
RL   Biochem. Soc. Trans. 38:205-208(2010).
RN   [33]
RP   FUNCTION.
RX   PubMed=20160076; DOI=10.1073/pnas.0913860107;
RA   Alexander A., Cai S.L., Kim J., Nanez A., Sahin M., MacLean K.H., Inoki K.,
RA   Guan K.L., Shen J., Person M.D., Kusewitt D., Mills G.B., Kastan M.B.,
RA   Walker C.L.;
RT   "ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to
RT   ROS.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4153-4158(2010).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [35]
RP   PHOSPHORYLATION BY ULK1 AND ULK2.
RX   PubMed=21460634; DOI=10.4161/auto.7.7.15451;
RA   Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M.,
RA   Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B.;
RT   "Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory
RT   feedback loop.";
RL   Autophagy 7:696-706(2011).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   FUNCTION IN PHOSPHORYLATION OF ULK1.
RX   PubMed=21205641; DOI=10.1126/science.1196371;
RA   Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A.,
RA   Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., Asara J.M.,
RA   Fitzpatrick J., Dillin A., Viollet B., Kundu M., Hansen M., Shaw R.J.;
RT   "Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects
RT   energy sensing to mitophagy.";
RL   Science 331:456-461(2011).
RN   [38]
RP   INTERACTION WITH PRKAB1 AND PRKAG1, AND ACTIVITY REGULATION.
RX   PubMed=21680840; DOI=10.1126/science.1200094;
RA   Oakhill J.S., Steel R., Chen Z.P., Scott J.W., Ling N., Tam S., Kemp B.E.;
RT   "AMPK is a direct adenylate charge-regulated protein kinase.";
RL   Science 332:1433-1435(2011).
RN   [39]
RP   REVIEW ON FUNCTION.
RX   PubMed=17307971; DOI=10.1161/01.res.0000256090.42690.05;
RA   Towler M.C., Hardie D.G.;
RT   "AMP-activated protein kinase in metabolic control and insulin signaling.";
RL   Circ. Res. 100:328-341(2007).
RN   [40]
RP   REVIEW ON FUNCTION.
RX   PubMed=17712357; DOI=10.1038/nrm2249;
RA   Hardie D.G.;
RT   "AMP-activated/SNF1 protein kinases: conserved guardians of cellular
RT   energy.";
RL   Nat. Rev. Mol. Cell Biol. 8:774-785(2007).
RN   [41]
RP   DEPHOSPHORYLATION.
RX   PubMed=23088624; DOI=10.1042/bj20121201;
RA   Chida T., Ando M., Matsuki T., Masu Y., Nagaura Y., Takano-Yamamoto T.,
RA   Tamura S., Kobayashi T.;
RT   "N-Myristoylation is essential for protein phosphatases PPM1A and PPM1B to
RT   dephosphorylate their physiological substrates in cells.";
RL   Biochem. J. 449:741-749(2013).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-32; THR-382; SER-486; THR-490
RP   AND SER-496, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-355; SER-496; SER-508;
RP   SER-524 AND SER-527, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [44]
RP   FUNCTION.
RX   PubMed=28561066; DOI=10.1038/ncomms15637;
RA   Bakula D., Mueller A.J., Zuleger T., Takacs Z., Franz-Wachtel M.,
RA   Thost A.K., Brigger D., Tschan M.P., Frickey T., Robenek H., Macek B.,
RA   Proikas-Cezanne T.;
RT   "WIPI3 and WIPI4 beta-propellers are scaffolds for LKB1-AMPK-TSC signalling
RT   circuits in the control of autophagy.";
RL   Nat. Commun. 8:15637-15637(2017).
RN   [45]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=32029622; DOI=10.1126/science.aay0542;
RA   Zhao P., Sun X., Chaggan C., Liao Z., In Wong K., He F., Singh S.,
RA   Loomba R., Karin M., Witztum J.L., Saltiel A.R.;
RT   "An AMPK-caspase-6 axis controls liver damage in nonalcoholic
RT   steatohepatitis.";
RL   Science 367:652-660(2020).
RN   [46]
RP   FUNCTION.
RX   PubMed=34077757; DOI=10.1016/j.molcel.2021.05.005;
RA   Liu R., Lee J.H., Li J., Yu R., Tan L., Xia Y., Zheng Y., Bian X.L.,
RA   Lorenzi P.L., Chen Q., Lu Z.;
RT   "Choline kinase alpha 2 acts as a protein kinase to promote lipolysis of
RT   lipid droplets.";
RL   Mol. Cell 81:2722-2735(2021).
RN   [47]
RP   VARIANT [LARGE SCALE ANALYSIS] ARG-16.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Catalytic subunit of AMP-activated protein kinase (AMPK), an
CC       energy sensor protein kinase that plays a key role in regulating
CC       cellular energy metabolism (PubMed:17307971, PubMed:17712357). In
CC       response to reduction of intracellular ATP levels, AMPK activates
CC       energy-producing pathways and inhibits energy-consuming processes:
CC       inhibits protein, carbohydrate and lipid biosynthesis, as well as cell
CC       growth and proliferation (PubMed:17307971, PubMed:17712357). AMPK acts
CC       via direct phosphorylation of metabolic enzymes, and by longer-term
CC       effects via phosphorylation of transcription regulators
CC       (PubMed:17307971, PubMed:17712357). Regulates lipid synthesis by
CC       phosphorylating and inactivating lipid metabolic enzymes such as ACACA,
CC       ACACB, GYS1, HMGCR and LIPE; regulates fatty acid and cholesterol
CC       synthesis by phosphorylating acetyl-CoA carboxylase (ACACA and ACACB)
CC       and hormone-sensitive lipase (LIPE) enzymes, respectively (By
CC       similarity). Promotes lipolysis of lipid droplets by mediating
CC       phosphorylation of isoform 1 of CHKA (CHKalpha2) (PubMed:34077757).
CC       Regulates insulin-signaling and glycolysis by phosphorylating IRS1,
CC       PFKFB2 and PFKFB3 (By similarity). AMPK stimulates glucose uptake in
CC       muscle by increasing the translocation of the glucose transporter
CC       SLC2A4/GLUT4 to the plasma membrane, possibly by mediating
CC       phosphorylation of TBC1D4/AS160 (By similarity). Regulates
CC       transcription and chromatin structure by phosphorylating transcription
CC       regulators involved in energy metabolism such as CRTC2/TORC2, FOXO3,
CC       histone H2B, HDAC5, MEF2C, MLXIPL/ChREBP, EP300, HNF4A, p53/TP53,
CC       SREBF1, SREBF2 and PPARGC1A (PubMed:11554766, PubMed:11518699,
CC       PubMed:15866171, PubMed:17711846, PubMed:18184930). Acts as a key
CC       regulator of glucose homeostasis in liver by phosphorylating
CC       CRTC2/TORC2, leading to CRTC2/TORC2 sequestration in the cytoplasm (By
CC       similarity). In response to stress, phosphorylates 'Ser-36' of histone
CC       H2B (H2BS36ph), leading to promote transcription (By similarity). Acts
CC       as a key regulator of cell growth and proliferation by phosphorylating
CC       TSC2, RPTOR and ATG1/ULK1: in response to nutrient limitation,
CC       negatively regulates the mTORC1 complex by phosphorylating RPTOR
CC       component of the mTORC1 complex and by phosphorylating and activating
CC       TSC2 (PubMed:14651849, PubMed:18439900, PubMed:20160076,
CC       PubMed:21205641). In response to nutrient limitation, promotes
CC       autophagy by phosphorylating and activating ATG1/ULK1
CC       (PubMed:21205641). In that process also activates WDR45/WIPI4
CC       (PubMed:28561066). Phosphorylates CASP6, thereby preventing its
CC       autoprocessing and subsequent activation (PubMed:32029622). In response
CC       to nutrient limitation, phosphorylates transcription factor FOXO3
CC       promoting FOXO3 mitochondrial import (By similarity). Also acts as a
CC       regulator of cellular polarity by remodeling the actin cytoskeleton;
CC       probably by indirectly activating myosin (PubMed:17486097). AMPK also
CC       acts as a regulator of circadian rhythm by mediating phosphorylation of
CC       CRY1, leading to destabilize it (By similarity). May regulate the Wnt
CC       signaling pathway by phosphorylating CTNNB1, leading to stabilize it
CC       (By similarity). Also has tau-protein kinase activity: in response to
CC       amyloid beta A4 protein (APP) exposure, activated by CAMKK2, leading to
CC       phosphorylation of MAPT/TAU; however the relevance of such data remains
CC       unclear in vivo (By similarity). Also phosphorylates CFTR, EEF2K, KLC1,
CC       NOS3 and SLC12A1 (PubMed:20074060, PubMed:12519745).
CC       {ECO:0000250|UniProtKB:P54645, ECO:0000250|UniProtKB:Q5EG47,
CC       ECO:0000269|PubMed:11518699, ECO:0000269|PubMed:11554766,
CC       ECO:0000269|PubMed:12519745, ECO:0000269|PubMed:14651849,
CC       ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:17486097,
CC       ECO:0000269|PubMed:17711846, ECO:0000269|PubMed:18184930,
CC       ECO:0000269|PubMed:18439900, ECO:0000269|PubMed:20074060,
CC       ECO:0000269|PubMed:20160076, ECO:0000269|PubMed:21205641,
CC       ECO:0000269|PubMed:28561066, ECO:0000269|PubMed:32029622,
CC       ECO:0000269|PubMed:34077757, ECO:0000303|PubMed:17307971,
CC       ECO:0000303|PubMed:17712357}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:32029622};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000250|UniProtKB:P54645};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[acetyl-CoA carboxylase] = ADP + H(+) + O-
CC         phospho-L-seryl-[acetyl-CoA carboxylase]; Xref=Rhea:RHEA:20333,
CC         Rhea:RHEA-COMP:13722, Rhea:RHEA-COMP:13723, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421,
CC         ChEBI:CHEBI:456216; EC=2.7.11.27;
CC         Evidence={ECO:0000250|UniProtKB:P54645};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[3-hydroxy-3-methylglutaryl-coenzyme A
CC         reductase] = ADP + H(+) + O-phospho-L-seryl-[3-hydroxy-3-
CC         methylglutaryl-coenzyme A reductase]; Xref=Rhea:RHEA:23172,
CC         Rhea:RHEA-COMP:13692, Rhea:RHEA-COMP:13693, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421,
CC         ChEBI:CHEBI:456216; EC=2.7.11.31;
CC         Evidence={ECO:0000250|UniProtKB:P54645};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[tau protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [tau protein]; Xref=Rhea:RHEA:12801, Rhea:RHEA-COMP:13701, Rhea:RHEA-
CC         COMP:13702, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.26;
CC         Evidence={ECO:0000250|UniProtKB:P54645};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[tau protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[tau protein]; Xref=Rhea:RHEA:53904, Rhea:RHEA-COMP:13703,
CC         Rhea:RHEA-COMP:13704, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.26; Evidence={ECO:0000250|UniProtKB:P54645};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation on Thr-183. Binding
CC       of AMP to non-catalytic gamma subunit (PRKAG1, PRKAG2 or PRKAG3)
CC       results in allosteric activation, inducing phosphorylation on Thr-183.
CC       AMP-binding to gamma subunit also sustains activity by preventing
CC       dephosphorylation of Thr-183. ADP also stimulates Thr-183
CC       phosphorylation, without stimulating already phosphorylated AMPK. ATP
CC       promotes dephosphorylation of Thr-183, rendering the enzyme inactive.
CC       Under physiological conditions AMPK mainly exists in its inactive form
CC       in complex with ATP, which is much more abundant than AMP. AMPK is
CC       activated by antihyperglycemic drug metformin, a drug prescribed to
CC       patients with type 2 diabetes: in vivo, metformin seems to mainly
CC       inhibit liver gluconeogenesis. However, metformin can be used to
CC       activate AMPK in muscle and other cells in culture or ex vivo
CC       (PubMed:11602624). Selectively inhibited by compound C (6-[4-(2-
CC       Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyyrazolo[1,5-a]
CC       pyrimidine. Activated by resveratrol, a natural polyphenol present in
CC       red wine, and S17834, a synthetic polyphenol.
CC       {ECO:0000269|PubMed:11602624, ECO:0000269|PubMed:14976552,
CC       ECO:0000269|PubMed:15980064, ECO:0000269|PubMed:16054095,
CC       ECO:0000269|PubMed:21680840}.
CC   -!- SUBUNIT: AMPK is a heterotrimer of an alpha catalytic subunit (PRKAA1
CC       or PRKAA2), a beta (PRKAB1 or PRKAB2) and a gamma non-catalytic
CC       subunits (PRKAG1, PRKAG2 or PRKAG3) (PubMed:21680840). Interacts with
CC       FNIP1 and FNIP2 (PubMed:17028174, PubMed:18403135, PubMed:18663353).
CC       {ECO:0000269|PubMed:17028174, ECO:0000269|PubMed:18403135,
CC       ECO:0000269|PubMed:18663353, ECO:0000269|PubMed:21680840}.
CC   -!- INTERACTION:
CC       Q13131; Q9NYB9: ABI2; NbExp=5; IntAct=EBI-1181405, EBI-743598;
CC       Q13131; O14503: BHLHE40; NbExp=3; IntAct=EBI-1181405, EBI-711810;
CC       Q13131; O14627: CDX4; NbExp=3; IntAct=EBI-1181405, EBI-10181162;
CC       Q13131; Q13363-2: CTBP1; NbExp=3; IntAct=EBI-1181405, EBI-10171858;
CC       Q13131; O95073: FSBP; NbExp=3; IntAct=EBI-1181405, EBI-1059030;
CC       Q13131; Q08379: GOLGA2; NbExp=3; IntAct=EBI-1181405, EBI-618309;
CC       Q13131; Q6NT76: HMBOX1; NbExp=3; IntAct=EBI-1181405, EBI-2549423;
CC       Q13131; Q8IX15-3: HOMEZ; NbExp=3; IntAct=EBI-1181405, EBI-10172004;
CC       Q13131; P08238: HSP90AB1; NbExp=2; IntAct=EBI-1181405, EBI-352572;
CC       Q13131; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-1181405, EBI-747204;
CC       Q13131; Q8NBZ0: INO80E; NbExp=3; IntAct=EBI-1181405, EBI-769401;
CC       Q13131; Q6A162: KRT40; NbExp=3; IntAct=EBI-1181405, EBI-10171697;
CC       Q13131; Q96JM7: L3MBTL3; NbExp=3; IntAct=EBI-1181405, EBI-2686809;
CC       Q13131; Q5JR59: MTUS2; NbExp=3; IntAct=EBI-1181405, EBI-742948;
CC       Q13131; Q8IXK0: PHC2; NbExp=3; IntAct=EBI-1181405, EBI-713786;
CC       Q13131; Q96PV4: PNMA5; NbExp=4; IntAct=EBI-1181405, EBI-10171633;
CC       Q13131; Q9Y478: PRKAB1; NbExp=9; IntAct=EBI-1181405, EBI-719769;
CC       Q13131; O43741: PRKAB2; NbExp=16; IntAct=EBI-1181405, EBI-1053424;
CC       Q13131; P54619: PRKAG1; NbExp=14; IntAct=EBI-1181405, EBI-1181439;
CC       Q13131; Q93062: RBPMS; NbExp=3; IntAct=EBI-1181405, EBI-740322;
CC       Q13131; Q8HWS3: RFX6; NbExp=3; IntAct=EBI-1181405, EBI-746118;
CC       Q13131; Q9UFD9: RIMBP3; NbExp=3; IntAct=EBI-1181405, EBI-10182375;
CC       Q13131; Q9HAT0: ROPN1; NbExp=4; IntAct=EBI-1181405, EBI-1378139;
CC       Q13131; Q9Y2D8: SSX2IP; NbExp=3; IntAct=EBI-1181405, EBI-2212028;
CC       Q13131; Q9NVV9: THAP1; NbExp=3; IntAct=EBI-1181405, EBI-741515;
CC       Q13131; Q08117: TLE5; NbExp=3; IntAct=EBI-1181405, EBI-717810;
CC       Q13131; P14373: TRIM27; NbExp=3; IntAct=EBI-1181405, EBI-719493;
CC       Q13131; Q15654: TRIP6; NbExp=3; IntAct=EBI-1181405, EBI-742327;
CC       Q13131; Q9Y3Q8: TSC22D4; NbExp=3; IntAct=EBI-1181405, EBI-739485;
CC       Q13131; Q5T124: UBXN11; NbExp=3; IntAct=EBI-1181405, EBI-746004;
CC       Q13131; Q9H9H4: VPS37B; NbExp=3; IntAct=EBI-1181405, EBI-4400866;
CC       Q13131; Q8N1B4: VPS52; NbExp=3; IntAct=EBI-1181405, EBI-2799833;
CC       Q13131; P46937: YAP1; NbExp=3; IntAct=EBI-1181405, EBI-1044059;
CC       Q13131; O96006: ZBED1; NbExp=3; IntAct=EBI-1181405, EBI-740037;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15866171}. Nucleus
CC       {ECO:0000269|PubMed:15866171}. Note=In response to stress, recruited by
CC       p53/TP53 to specific promoters. {ECO:0000269|PubMed:15866171}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13131-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13131-2; Sequence=VSP_035431;
CC   -!- DOMAIN: The AIS (autoinhibitory sequence) region shows some sequence
CC       similarity with the ubiquitin-associated domains and represses kinase
CC       activity. {ECO:0000269|PubMed:17088252, ECO:0000269|PubMed:9857077}.
CC   -!- PTM: Ubiquitinated. {ECO:0000250|UniProtKB:Q5EG47}.
CC   -!- PTM: Phosphorylated at Thr-183 by STK11/LKB1 in complex with STE20-
CC       related adapter-alpha (STRADA) pseudo kinase and CAB39. Also
CC       phosphorylated at Thr-183 by CAMKK2; triggered by a rise in
CC       intracellular calcium ions, without detectable changes in the AMP/ATP
CC       ratio. CAMKK1 can also phosphorylate Thr-183, but at a much lower
CC       level. Dephosphorylated by protein phosphatase 2A and 2C (PP2A and
CC       PP2C). Phosphorylated by ULK1 and ULK2; leading to negatively regulate
CC       AMPK activity and suggesting the existence of a regulatory feedback
CC       loop between ULK1, ULK2 and AMPK. Dephosphorylated by PPM1A and PPM1B.
CC       {ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:15980064,
CC       ECO:0000269|PubMed:16054095, ECO:0000269|PubMed:21460634}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. SNF1 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA64850.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAD43027.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAH37303.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAA36547.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAG35788.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC008810; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC048980; AAH48980.1; -; mRNA.
DR   EMBL; AB022017; BAA36547.1; ALT_INIT; mRNA.
DR   EMBL; AK312947; BAG35788.1; ALT_INIT; mRNA.
DR   EMBL; BC037303; AAH37303.1; ALT_INIT; mRNA.
DR   EMBL; AF100763; AAD43027.1; ALT_INIT; mRNA.
DR   EMBL; U22456; AAA64850.1; ALT_INIT; mRNA.
DR   EMBL; Y12856; CAA73361.1; -; mRNA.
DR   CCDS; CCDS3932.2; -. [Q13131-1]
DR   CCDS; CCDS3933.2; -. [Q13131-2]
DR   PIR; G01743; G01743.
DR   RefSeq; NP_006242.5; NM_006251.5. [Q13131-1]
DR   RefSeq; NP_996790.3; NM_206907.3. [Q13131-2]
DR   PDB; 4RED; X-ray; 2.95 A; A/B=22-362.
DR   PDB; 4RER; X-ray; 4.05 A; A=20-559.
DR   PDB; 4REW; X-ray; 4.58 A; A=20-559.
DR   PDB; 5EZV; X-ray; 2.99 A; A/C=359-401.
DR   PDB; 6C9F; X-ray; 2.92 A; A=22-559.
DR   PDB; 6C9G; X-ray; 2.70 A; A=22-559.
DR   PDB; 6C9H; X-ray; 2.65 A; A=22-559.
DR   PDB; 6C9J; X-ray; 3.05 A; A=22-559.
DR   PDB; 7JHG; EM; 3.47 A; A=22-559.
DR   PDB; 7JHH; EM; 3.92 A; A=22-559.
DR   PDB; 7JIJ; X-ray; 5.50 A; A=22-559.
DR   PDBsum; 4RED; -.
DR   PDBsum; 4RER; -.
DR   PDBsum; 4REW; -.
DR   PDBsum; 5EZV; -.
DR   PDBsum; 6C9F; -.
DR   PDBsum; 6C9G; -.
DR   PDBsum; 6C9H; -.
DR   PDBsum; 6C9J; -.
DR   PDBsum; 7JHG; -.
DR   PDBsum; 7JHH; -.
DR   PDBsum; 7JIJ; -.
DR   AlphaFoldDB; Q13131; -.
DR   SMR; Q13131; -.
DR   BioGRID; 111549; 246.
DR   ComplexPortal; CPX-5633; AMPK complex, alpha1-beta1-gamma1 variant.
DR   ComplexPortal; CPX-5786; AMPK complex, alpha1-beta1-gamma2 variant.
DR   ComplexPortal; CPX-5791; AMPK complex, alpha1-beta2-gamma1 variant.
DR   ComplexPortal; CPX-5841; AMPK complex, alpha1-beta2-gamma3 variant.
DR   ComplexPortal; CPX-5842; AMPK complex, alpha1-beta1-gamma3 variant.
DR   ComplexPortal; CPX-5846; AMPK complex, alpha1-beta2-gamma2 variant.
DR   CORUM; Q13131; -.
DR   DIP; DIP-39973N; -.
DR   IntAct; Q13131; 122.
DR   MINT; Q13131; -.
DR   STRING; 9606.ENSP00000346148; -.
DR   BindingDB; Q13131; -.
DR   ChEMBL; CHEMBL4045; -.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB00131; Adenosine phosphate.
DR   DrugBank; DB00171; ATP.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB00914; Phenformin.
DR   DrugBank; DB00273; Topiramate.
DR   DrugCentral; Q13131; -.
DR   GlyGen; Q13131; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q13131; -.
DR   PhosphoSitePlus; Q13131; -.
DR   BioMuta; PRKAA1; -.
DR   DMDM; 254763436; -.
DR   EPD; Q13131; -.
DR   jPOST; Q13131; -.
DR   MassIVE; Q13131; -.
DR   MaxQB; Q13131; -.
DR   PaxDb; Q13131; -.
DR   PeptideAtlas; Q13131; -.
DR   PRIDE; Q13131; -.
DR   ProteomicsDB; 59180; -. [Q13131-1]
DR   ProteomicsDB; 59181; -. [Q13131-2]
DR   ABCD; Q13131; 1 sequenced antibody.
DR   Antibodypedia; 3564; 1472 antibodies from 45 providers.
DR   DNASU; 5562; -.
DR   Ensembl; ENST00000354209.7; ENSP00000346148.3; ENSG00000132356.12. [Q13131-2]
DR   Ensembl; ENST00000397128.7; ENSP00000380317.2; ENSG00000132356.12. [Q13131-1]
DR   GeneID; 5562; -.
DR   KEGG; hsa:5562; -.
DR   MANE-Select; ENST00000397128.7; ENSP00000380317.2; NM_006251.6; NP_006242.5.
DR   UCSC; uc003jmb.4; human. [Q13131-1]
DR   CTD; 5562; -.
DR   DisGeNET; 5562; -.
DR   GeneCards; PRKAA1; -.
DR   HGNC; HGNC:9376; PRKAA1.
DR   HPA; ENSG00000132356; Low tissue specificity.
DR   MIM; 602739; gene.
DR   neXtProt; NX_Q13131; -.
DR   OpenTargets; ENSG00000132356; -.
DR   PharmGKB; PA33744; -.
DR   VEuPathDB; HostDB:ENSG00000132356; -.
DR   eggNOG; KOG0583; Eukaryota.
DR   GeneTree; ENSGT00940000158865; -.
DR   HOGENOM; CLU_000288_59_3_1; -.
DR   OMA; HHFTRPH; -.
DR   OrthoDB; 1127668at2759; -.
DR   PhylomeDB; Q13131; -.
DR   TreeFam; TF314032; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   BRENDA; 2.7.11.31; 2681.
DR   PathwayCommons; Q13131; -.
DR   Reactome; R-HSA-1632852; Macroautophagy.
DR   Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-9619483; Activation of AMPK downstream of NMDARs.
DR   SignaLink; Q13131; -.
DR   SIGNOR; Q13131; -.
DR   BioGRID-ORCS; 5562; 25 hits in 1107 CRISPR screens.
DR   ChiTaRS; PRKAA1; human.
DR   GeneWiki; Protein_kinase,_AMP-activated,_alpha_1; -.
DR   GenomeRNAi; 5562; -.
DR   Pharos; Q13131; Tclin.
DR   PRO; PR:Q13131; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q13131; protein.
DR   Bgee; ENSG00000132356; Expressed in calcaneal tendon and 176 other tissues.
DR   ExpressionAtlas; Q13131; baseline and differential.
DR   Genevisible; Q13131; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0030424; C:axon; ISS:ARUK-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:ARUK-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; ISS:ARUK-UCL.
DR   GO; GO:0043025; C:neuronal cell body; ISS:ARUK-UCL.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0031588; C:nucleotide-activated protein kinase complex; IPI:ComplexPortal.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0050405; F:[acetyl-CoA carboxylase] kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0047322; F:[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004679; F:AMP-activated protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004691; F:cAMP-dependent protein kinase activity; NAS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0035174; F:histone serine kinase activity; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008022; F:protein C-terminus binding; IEA:Ensembl.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0048156; F:tau protein binding; NAS:ARUK-UCL.
DR   GO; GO:0050321; F:tau-protein kinase activity; NAS:ARUK-UCL.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0015721; P:bile acid and bile salt transport; IEA:Ensembl.
DR   GO; GO:0038183; P:bile acid signaling pathway; IEA:Ensembl.
DR   GO; GO:0061762; P:CAMKK-AMPK signaling cascade; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0071277; P:cellular response to calcium ion; ISS:ARUK-UCL.
DR   GO; GO:0071361; P:cellular response to ethanol; IEA:Ensembl.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; ISS:ARUK-UCL.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0031669; P:cellular response to nutrient levels; IDA:ComplexPortal.
DR   GO; GO:0071417; P:cellular response to organonitrogen compound; IEA:Ensembl.
DR   GO; GO:0034599; P:cellular response to oxidative stress; ISS:ARUK-UCL.
DR   GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl.
DR   GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW.
DR   GO; GO:0009631; P:cold acclimation; IEA:Ensembl.
DR   GO; GO:0097009; P:energy homeostasis; ISS:UniProtKB.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0055089; P:fatty acid homeostasis; ISS:UniProtKB.
DR   GO; GO:0019395; P:fatty acid oxidation; IEA:Ensembl.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0008610; P:lipid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:1905691; P:lipid droplet disassembly; IDA:UniProtKB.
DR   GO; GO:0061744; P:motor behavior; IGI:ARUK-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISS:ARUK-UCL.
DR   GO; GO:0046318; P:negative regulation of glucosylceramide biosynthetic process; NAS:UniProtKB.
DR   GO; GO:1903944; P:negative regulation of hepatocyte apoptotic process; IDA:UniProtKB.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0050995; P:negative regulation of lipid catabolic process; ISS:UniProtKB.
DR   GO; GO:0032007; P:negative regulation of TOR signaling; ISS:UniProtKB.
DR   GO; GO:1904428; P:negative regulation of tubulin deacetylation; ISS:ARUK-UCL.
DR   GO; GO:0070050; P:neuron cellular homeostasis; IGI:ARUK-UCL.
DR   GO; GO:0010508; P:positive regulation of autophagy; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0045542; P:positive regulation of cholesterol biosynthetic process; NAS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; ISS:UniProtKB.
DR   GO; GO:1903109; P:positive regulation of mitochondrial transcription; IEA:Ensembl.
DR   GO; GO:2000758; P:positive regulation of peptidyl-lysine acetylation; ISS:ARUK-UCL.
DR   GO; GO:1903829; P:positive regulation of protein localization; ISS:ARUK-UCL.
DR   GO; GO:1903955; P:positive regulation of protein targeting to mitochondrion; IEA:Ensembl.
DR   GO; GO:0048643; P:positive regulation of skeletal muscle tissue development; IEA:Ensembl.
DR   GO; GO:1990044; P:protein localization to lipid droplet; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0120188; P:regulation of bile acid secretion; IEA:Ensembl.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; ISS:ARUK-UCL.
DR   GO; GO:0033135; P:regulation of peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0062028; P:regulation of stress granule assembly; IEA:Ensembl.
DR   GO; GO:0060627; P:regulation of vesicle-mediated transport; IEA:Ensembl.
DR   GO; GO:1904486; P:response to 17alpha-ethynylestradiol; IEA:Ensembl.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0031000; P:response to caffeine; IEA:Ensembl.
DR   GO; GO:1901563; P:response to camptothecin; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; ISS:UniProtKB.
DR   GO; GO:0001666; P:response to hypoxia; NAS:UniProtKB.
DR   GO; GO:0009411; P:response to UV; IEA:Ensembl.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   CDD; cd12199; AMPKA1_C; 1.
DR   CDD; cd14403; UBA_AID_AAPK1; 1.
DR   InterPro; IPR032270; AMPK_C.
DR   InterPro; IPR039137; AMPKA1_C.
DR   InterPro; IPR028375; KA1/Ssp2_C.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR028797; PRKAA1_UBA.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF16579; AdenylateSensor; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF103243; SSF103243; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Autophagy;
KW   Biological rhythms; Cholesterol biosynthesis; Cholesterol metabolism;
KW   Chromatin regulator; Cytoplasm; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Kinase; Lipid biosynthesis; Lipid metabolism;
KW   Magnesium; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Steroid biosynthesis;
KW   Steroid metabolism; Sterol biosynthesis; Sterol metabolism; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation;
KW   Wnt signaling pathway.
FT   CHAIN           1..559
FT                   /note="5'-AMP-activated protein kinase catalytic subunit
FT                   alpha-1"
FT                   /id="PRO_0000085589"
FT   DOMAIN          27..279
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          302..381
FT                   /note="AIS"
FT   REGION          485..536
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        150
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         33..41
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         56
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         32
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         183
FT                   /note="Phosphothreonine; by LKB1 and CaMKK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q5EG47"
FT   MOD_RES         269
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P54645"
FT   MOD_RES         355
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         356
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         360
FT                   /note="Phosphoserine; by ULK1"
FT                   /evidence="ECO:0000250|UniProtKB:P54645"
FT   MOD_RES         368
FT                   /note="Phosphothreonine; by ULK1"
FT                   /evidence="ECO:0000250|UniProtKB:P54645"
FT   MOD_RES         382
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         397
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P54645"
FT   MOD_RES         467
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         486
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         488
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P54645"
FT   MOD_RES         490
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         496
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         508
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         524
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         527
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         121
FT                   /note="R -> RKSDVPGVVKTGSTKE (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_035431"
FT   VARIANT         10
FT                   /note="M -> L (in dbSNP:rs17855679)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_058401"
FT   VARIANT         16
FT                   /note="Q -> R (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs928784854)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035622"
FT   MUTAGEN         307
FT                   /note="V->G,Q: Activates the kinase activity."
FT                   /evidence="ECO:0000269|PubMed:17088252"
FT   CONFLICT        5
FT                   /note="S -> C (in Ref. 4; BAG35788)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        9
FT                   /note="K -> S (in Ref. 5; AAD43027)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        37
FT                   /note="T -> A (in Ref. 6; AAA64850)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        202
FT                   /note="A -> V (in Ref. 6; AAA64850)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        208
FT                   /note="I -> L (in Ref. 6; AAA64850)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        269
FT                   /note="T -> S (in Ref. 3; BAA36547)"
FT                   /evidence="ECO:0000305"
FT   STRAND          27..34
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   STRAND          37..39
FT                   /evidence="ECO:0007829|PDB:6C9G"
FT   STRAND          41..46
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   TURN            47..49
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   STRAND          52..59
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   HELIX           60..65
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   HELIX           69..81
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   STRAND          90..95
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   STRAND          97..105
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   STRAND          108..111
FT                   /evidence="ECO:0007829|PDB:6C9J"
FT   HELIX           112..119
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   HELIX           124..143
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   TURN            153..155
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   STRAND          156..158
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   STRAND          164..166
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   HELIX           169..171
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   HELIX           173..178
FT                   /evidence="ECO:0007829|PDB:7JHG"
FT   HELIX           180..186
FT                   /evidence="ECO:0007829|PDB:7JHG"
FT   TURN            188..190
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   HELIX           193..196
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   HELIX           204..220
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   STRAND          227..229
FT                   /evidence="ECO:0007829|PDB:4RED"
FT   HELIX           230..239
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   STRAND          246..248
FT                   /evidence="ECO:0007829|PDB:7JHG"
FT   HELIX           250..259
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   TURN            264..266
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   HELIX           270..275
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   HELIX           277..280
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   HELIX           285..287
FT                   /evidence="ECO:0007829|PDB:6C9G"
FT   HELIX           298..305
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   TURN            323..325
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   HELIX           330..345
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   HELIX           349..351
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   TURN            372..374
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   HELIX           375..379
FT                   /evidence="ECO:0007829|PDB:6C9J"
FT   STRAND          408..413
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   HELIX           417..430
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   STRAND          434..439
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   STRAND          442..448
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   TURN            450..452
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   STRAND          455..464
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   STRAND          466..468
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   STRAND          470..476
FT                   /evidence="ECO:0007829|PDB:6C9H"
FT   HELIX           542..557
FT                   /evidence="ECO:0007829|PDB:6C9H"
SQ   SEQUENCE   559 AA;  64009 MW;  ABAE71FBF912947A CRC64;
     MRRLSSWRKM ATAEKQKHDG RVKIGHYILG DTLGVGTFGK VKVGKHELTG HKVAVKILNR
     QKIRSLDVVG KIRREIQNLK LFRHPHIIKL YQVISTPSDI FMVMEYVSGG ELFDYICKNG
     RLDEKESRRL FQQILSGVDY CHRHMVVHRD LKPENVLLDA HMNAKIADFG LSNMMSDGEF
     LRTSCGSPNY AAPEVISGRL YAGPEVDIWS SGVILYALLC GTLPFDDDHV PTLFKKICDG
     IFYTPQYLNP SVISLLKHML QVDPMKRATI KDIREHEWFK QDLPKYLFPE DPSYSSTMID
     DEALKEVCEK FECSEEEVLS CLYNRNHQDP LAVAYHLIID NRRIMNEAKD FYLATSPPDS
     FLDDHHLTRP HPERVPFLVA ETPRARHTLD ELNPQKSKHQ GVRKAKWHLG IRSQSRPNDI
     MAEVCRAIKQ LDYEWKVVNP YYLRVRRKNP VTSTYSKMSL QLYQVDSRTY LLDFRSIDDE
     ITEAKSGTAT PQRSGSVSNY RSCQRSDSDA EAQGKSSEVS LTSSVTSLDS SPVDLTPRPG
     SHTIEFFEMC ANLIKILAQ
//
